ライフサイエンスコーパス: inotrope

1 ulatory support, or hospital discharge on an inotrope.

2 as been shown ex vivo to be a potent cardiac inotrope.

3 /- 63.1 vs. 215.5 +/- 68.1), and duration of inotrope.

4 d lower cumulative doses of vasopressors and inotropes.

5 or to that of patients who were bridged with inotropes.

6 cts that are commonly observed with positive inotropes.

7 anted, 32 received LVADs, and 50 remained on inotropes.

8 evaluates contemporary outcomes on long-term inotropes.

9 in patients who were offered LVAD but chose inotropes (15 patients), and for palliation (98 patients

10 dy, 68 patients had died, 24 were weaned off inotropes, 23 were transplanted, 32 received LVADs, and

11 ortic balloon pump usage (8.5% versus 7.5%), inotrope (39% versus 50%) and vasoconstrictor usage (66%

12 male patients), patients were on 2.0 +/- 0.9 inotropes, 7 (35) had an intra-aortic balloon pump, 2 we

13 tilation, 8% versus 19%; vasopressors and/or inotropes, 9% versus 16%; vasodilators, 6% versus 12%; a

14 then manipulated by fluid administration or inotrope adjustment, and the readings were repeated.

15 therapy, a higher percentage were prescribed inotropes after publication (3272 [21.5%] of 15 193 pati

16 Although the use of inotropes also decreased during the period under study,

17 We conclude that beta-MyHC is a negative inotrope among the cardiac myofilament proteins.

18 Combination therapy with a positive inotrope and a beta-blocker appears to be useful in the

19 s ratio: 1.5; p < 0.0001) compared with dual-inotrope and intra-aortic balloon pump support.

20 Score II, even when assessing the effect of inotrope and vasoactive treatments at 24, 48, and 72 hou

21 r and peak cTnT, ECG changes, cardiac index, inotrope and vasoconstrictor use, renal dysfunction, and

22 the DCDD group, donor age < 40 years, use of inotropes and absence of gag/cough reflexes were predict

23 or poor ejection fraction, and the need for inotropes and an intra-aortic balloon pump (OR 1.72 to 4

24 etween mortality and compliance with each of inotropes and red cell transfusions, glucocorticoids, an

25 Status 1A registrants supported with dual inotropes and right heart monitoring had a higher risk o

26 hat cooling can reduce the need for positive inotropes and that lower rather than higher temperatures

27 Twenty-one patients required intravenous inotropes and three patients required extracorporeal mem

28 ) over 5 to 10 mins (2C); more common use of inotropes and vasodilators for low cardiac output septic

29 es the use of vasoactive medications such as inotropes and vasodilators.

30 eart rate of >120 beats/min, requirement for inotropes and vasopressors after surgery and on admissio

31 Inotropes and vasopressors are widely used to improve he

32 All inotropes and vasopressors were discontinued within 12 h

33 Inotropes and vasopressors were not administered to eith

34 et of symptoms <1 month) of whom 55 required inotropes and/or mechanical circulatory support (FM) and

35 th longer ischemic times, longer duration of inotrope, and correspond with higher glucose levels.

36 Goal-directed therapy using fluids, inotropes, and blood transfusion reduced 30-day major co

37 , in which intravenous fluids, vasopressors, inotropes, and blood transfusions were adjusted to reach

38 the use of intravenous fluids, vasopressors, inotropes, and blood transfusions.

39 iod; administration of fluids, vasopressors, inotropes, and packed red blood cells titrated to hemody

40 rgery, mechanical ventilation, vasopressors, inotropes, and pulmonary vasodilators.

41 than 3 L/min/m was targeted with IV fluids, inotropes, and RBC transfusion starting from cardiopulmo

42 ristics, hemodynamic and clinical changes on inotropes, and survival were evaluated.

43 Crystalloids, colloids, blood, inotropes, and vasopressors were used by predetermined a

44 risk (P=0.012 and P=0.006 compared with non-inotrope- and inotrope-based controls, respectively), as

45 0.003) or any control therapy, including non-inotrope- and inotrope-based therapies (RR(MH), 1.54; 95

46 Inotropes are effective as a bridge to transplant/LVAD.

47 hat increase cardiac contractility (positive inotropes) are theoretically appealing as a heart failur

48 lume index of <30 mL/min/m2, requirement for inotropes, arterial bicarbonate of <20 mmol/L, plasma gl

49 ion fraction <30%, pre-operative intravenous inotropes, arterial vascular disease, and higher degree

50 Of 60 patients who were placed on inotropes as a bridge to transplant/LVAD, 55 were succes

51 effects and to determine in vivo efficacy of inotropes as anti-inflammatory agents.

52 Based on these data, the routine use of inotropes as heart failure therapy is not indicated in e

53 LOF was defined as the need for >/=2 inotropes at 48 hours, an intra- or post-operative intra

54 (OR, 1.5; 95% CI, 1.1-2.0), support with >/=inotropes at HT (OR, 1.7; 95% CI, 1.2-2.5), hospitalizat

55 f worsening renal function compared with non-inotrope-based control (RR(MH), 1.52; 95% CI, 1.16 to 2.

56 and P=0.006 compared with non-inotrope- and inotrope-based controls, respectively), as did nesiritid

57 control therapy, including non-inotrope- and inotrope-based therapies (RR(MH), 1.54; 95% CI, 1.19 to

58 scular problems from overuse of diuretics or inotropes because of the unusual loading conditions in T

59 Positive inotropes, beta1-AR agonists, are used to improve cardia

60 tinotrope data on 197 patients discharged on inotropes between January 2007 and March 2013.

61 but include medical therapy with intravenous inotropes, biventricular assist devices (Bi-VADs) and th

62 Dobutamine was superior to dopamine as an RV inotrope, both ex vivo and in vivo.

63 Concurrently, the status 1A inotrope candidate waitlist outcomes improved substantia

64 waitlist death or deterioration of status 1A inotrope candidates relative to status 2 candidates decr

65 to determine whether candidates listed with inotropes contribute to the excess status 1A candidates.

66 nds suggest that overtreatment with multiple inotropes contributes to the current critical excess of

67 levant concentrations of stress hormones and inotropes could directly affect the iron binding of seru

68 In contrast to existing pharmacological inotropes, CRT both acutely and chronically increases ca

69 all cause mortality, retransplantation, and inotrope dependence.

70 n of Nontransplant-Eligible Patients Who Are Inotrope Dependent) trial was a prospective, nonrandomiz

71 ntubated and on prostaglandin, 24 (89%) were inotrope dependent, and 22 (81%) had no antegrade flow f

72 Survival was best in patients who were not inotrope-dependent (INTERMACS profiles 4 to 7).

73 In non-inotrope-dependent advanced heart failure patients recei

74 ) support on survival and quality of life in inotrope-dependent heart failure patients ineligible for

75 Inotrope-dependent heart failure patients who are inelig

76 eligible patients, mean life expectancy with inotrope-dependent medical therapy is estimated at 9.4 m

77 options for end-stage heart failure include inotrope-dependent medical therapy, orthotopic heart tra

78 ality-adjusted life-year gained, relative to inotrope-dependent medical therapy.

79 ality-adjusted life-year gained, relative to inotrope-dependent medical therapy.

80 </= 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical management, or lis

81 , United Network for Organ Sharing status I (inotrope-dependent) heart transplant (n = 3) or urgent i

82 Neutrophil pretreatment with inotropes did not prevent CD11b upregulation.

83 , antibacterials, narcotics, antipsychotics, inotropes, digoxin, anesthetic agents, bronchodilators,

84 therapy algorithm for intravenous fluid and inotrope (dopexamine) infusion during and 6 hours follow

85 Increase in inotrope dose significantly increased spinal cord perfus

86 d for either mechanical support or high-dose inotrope (epinephrine > or = 0.07 microg/kg/min).

87 al differences; broadly, ssTnI is a positive inotrope, especially under acidic/hypoxic conditions, wh

88 Patients who received inotropes for palliation or those who preferred inotrope

89 Survival on inotropes for patients who are not candidates for transp

90 13 [0-25] vs 15 [0-25]; p = 0.8) and pressor/inotrope-free days (median and interquartile range, 25 [

91 eaths) and 65 +/- 10% at three years for the inotrope group (nine deaths; p = 0.007).

92 D group and 44 +/- 9% at three years for the inotrope group (p = 0.01).

93 hs for the LVAD group and 64 +/- 11% for the inotrope group (p = NS).

94 Patients initiated on inotropes had refractory heart failure, with median base

95 Catecholaminergic inotropes have a place in the management of low output s

96 Inotropes have been fundamental to resuscitation of acut

97 7; P=0.003), defect size (HR=1.09; P=0.026), inotropes (HR=4.18; P=0.005), and absence of revasculari

98 troglycerin, nitroprusside), and intravenous inotropes (ie, dobutamine, milrinone).

99 Endothelin-1 (ET-1) is a potent positive inotrope in vitro, but its physiological effects on intr

100 cubation of S epidermidis with catecholamine inotropes in the presence of human plasma resulted in a

101 goal-directed therapy with vasopressors and inotropes in the treatment of sepsis syndrome.

102 eceiving multiple catecholamine pressors and inotropes, including dobutamine (n=10), epinephrine (n=8

103 Positive inotropes, including phosphodiesterase inhibitors, are a

104 umber of candidates listed as status 1A with inotropes increased by 193 a year, whereas the dobutamin

105 cal generalized linear models (0.113 for any inotrope) indicated that a noteworthy proportion of the

106 mediated cardiac contractile dysfunction and inotrope insensitivity.

107 rapy, bridging to heart transplantation with inotropes is thought to be the preferred treatment optio

108 on in advanced heart failure patients not on inotropes is unclear.

109 In contrast to available inotropes, istaroxime increased SBP and decreased HR.

110 Inotropes may be a necessary evil in a subset of acute h

111 ren were supported with multiple intravenous inotropes+/-mechanical ventilation (6) or ECMO (3) befor

112 spitalization for heart failure, intravenous inotropes, mechanical support, or death.

113 dverse clinical outcomes, including need for inotropes, mechanical ventilation, meningitis, and death

114 dged to heart transplantation with either IV inotropes (n = 38) or an implantable LVAD (n = 66; Heart

115 were not taking beta-blockers or intravenous inotropes (n=470) were followed for 1.5 years.

116 val 1.04 to 1.17; p = .005), and infusion of inotropes (odds ratio 4.7; 95% confidence interval 1.3 t

117 brane oxygenation cardiac arrest, the use of inotropes on extracorporeal membrane oxygenation, and po

118 Seven patients (22%) required inotropes on leaving the operating room, and 3 patients

119 ardiovascular effects of a novel intravenous inotrope, OPC-18790, the observed benefits on contractil

120 transplantation with either intravenous (IV) inotropes or an implantable left ventricular assist devi

121 t failure needing intravenous treatment with inotropes or diuretics was the most common adverse event

122 differences in the administration of either inotropes or RBC transfusions.

123 Under these circumstances, treatment with inotropes or renal vasodilators may be more appropriate

124 A total of 55 patients were receiving inotropes or vasodilators.

125 emoglobin >8 g/dL, and no use of intravenous inotropes or vasopressors.

126 5%, cardiac index </= 2.2 l/min/m(2) without inotropes or were inotrope-dependent on optimal medical

127 a central venous catheter, administration of inotropes, or blood transfusions; or usual care.

128 , or any intravenous therapy with diuretics, inotropes, or other vasoactive agents.

129 ATPase-inhibitor, or the calcium-sensitizing inotrope ORG 30029.

130 tropes for palliation or those who preferred inotropes over LVAD had median survival of 9.0 months (i

131 p required more fluid boluses (p < 0.05) and inotropes (p < 0.001).

132 acidosis (P:=0.03), need for bicarbonate or inotropes (P:=0.008 and 0.04), and ventricular dysfuncti

133 PaO2/FIO2 less than 300, use of vasopressors/inotropes, pancreatitis, hepatic failure/cirrhosis with

134 creatinine concentration >3.0 mg/dL, use of inotropes, presence of myocardial stun, and requirement

135 led Doppler-derived risk groups, intravenous inotrope requirement and blood urea nitrogen as signific

136 ICU admission and predicts ICU mortality and inotrope requirement as well as or better than APACHE II

137 ACR 2 predicted mortality and ACR 1 inotrope requirement independent of clinical mortality r

138 was associated with reductions in procedural inotrope requirement, intensive care unit and hospital l

139 unit stay (p = 0.175), survival (p = 0.877), inotrope requirements (p = 0.495), need for extracorpore

140 patients with the TAH have no postoperative inotrope requirements, arrhythmias or inflow/outflow can

141 nical ventilation and biochemical variables, inotrope requirements, extracorporeal membrane oxygenati

142 terio-venous O2 difference (DeltaA-VO2), and inotrope requirements.

143 tive transthoracic echocardiography and peak inotrope requirements.

144 In maladaptive RVH there is reduced inotrope responsiveness because of G-protein receptor ki

145 in both rat and human myocytes, but restored inotrope responsiveness.

146 vity assay of serum troponin T at 72 hours), inotrope score (calculated from the maximum dose of the

147 FIO2, oxygenation index, and 24-hour maximal inotrope score (p</=0.02), although end-tidal alveolar d

148 aO2/FIO2, oxygenation index, 24-hour maximal inotrope score, and Pediatric Risk of Mortality III (all

149 nation of oxygenation index, 24-hour maximal inotrope score, and Pediatric Risk of Mortality III.

150 nation of oxygenation index, 24-hour maximal inotrope score, and Pediatric Risk of Mortality III.

151 Hemodynamics, inotrope score, and serum sodium did not differ between

152 ore-1, Pediatric Logistic Organ Dysfunction, inotrope score, duration of ventilation and pediatric IC

153 t ventricular (RV) adrenergic remodeling for inotrope selection and the therapeutic benefit of interr

154 100 versus 107 mm Hg in those not receiving inotropes, serum sodium was 134 versus 137 mEq/L, and le

155 d Circulatory Support class, use of multiple inotropes, severe right ventricular dysfunction on echoc

156 a possible mechanism by which catecholamine inotropes stimulate bacterial growth as biofilms.

157 n in both adrenergic receptor expression and inotrope-stimulated cAMP levels (P<0.01).

158 While inotropes successfully increase cardiac output, their us

159 d that clinically relevant concentrations of inotropes, such as amrinone and dopamine, which increase

160 Currently available inotropes, such as dobutamine and milrinone, act (direct

161 .25]; RD, -0.09 [95% CI, -0.22 to 0.05]), or inotrope support (RR, 0.77 [95% CI, 0.51 to 1.17]; RD, -

162 d as the need for post-operative intravenous inotrope support for >14 days, inhaled nitric oxide for

163 (95% confidence interval: 4% to 8%) for dual inotrope support.

164 neutrophils were pretreated with or without inotropes, then stimulated with n-formyl methyl leucine

165 ive iron showed the ability of catecholamine inotropes to facilitate acquisition of iron by S epiderm

166 s in 2006, transplant programs used multiple inotropes to list candidates at status 1A more frequentl

167 ability of catecholamine stress hormones and inotropes to stimulate the growth of infectious bacteria

168 Myocardial failure, leading to inotrope-unresponsive shock, is the predominant cause of

169 ant/LVAD, 55 were successfully maintained on inotropes until transplant/LVAD.

170 pass, 2.6%; intraaortic balloon pumps, 1.0%; inotrope usage, 0.8%; combination, 1.0%).

171 trograde cardioplegia had significantly less inotrope use (71% versus 84%, P:=0.002), right ventricul

172 ), a medical diagnosis (hazard ratio, 1.43), inotrope use (hazard ratio, 3.47), and treatment limitat

173 % CI, 1.2-8.2), and had a longer duration of inotrope use (median, 5.5 [IQR, 4-8] vs 4.0 [IQR, 3-6] d

174 1 to 5.70; P<0.001), intraoperative multiple inotrope use (OR, 2.75; CI, 1.75 to 4.31; P<0.001), intr

175 Inotrope use (score) was higher in the PGD group at 24,

176 47; P=0.0001) and a significant reduction in inotrope use 6 to 12 hours postoperatively (odds ratio,

177 t to characterize institutional variation in inotrope use among patients hospitalized with heart fail

178 sociation between risk-standardized rates of inotrope use and clinical outcomes was determined.

179 te hospital-level risk-standardized rates of inotrope use and risk-standardized in-hospital mortality

180 y of atrial fibrillation, those who required inotrope use during or after surgery, and those having v

181 , including mean arterial blood pressure and inotrope use during the 48 h after hypoxia-ischaemia.

182 Hospitals with higher risk-standardized inotrope use had modestly longer risk-standardized lengt

183 Inotrope use in heart failure treatment was associated w

184 The risk-standardized rates of inotrope use ranged across hospitals from 0.9% to 44.6%

185 icated that 21% of the observed variation in inotrope use was potentially attributable to random hosp

186 Patterns of inotrope use were stable during the 7-year study period.

187 ed risk-standardized hospital-level rates of inotrope use within 209 hospitals participating in Get W

188 trolling for severity of oxygenation defect, inotrope use, and severity of illness.

189 l ventilation, intensive care unit stay, and inotrope use; and fewer electrolyte abnormalities.

190 Use of inotropes varied significantly between hospitals even af

191 Inotropes, vasodilators (children), inhaled nitric oxide

192 ial diuretic requirement despite intravenous inotropes/vasodilators.

193 ho have metabolic acidosis, a bicarbonate or inotrope/vasopressor requirement, cardiopulmonary resusc

194 emography, clinical classification, outcome, inotrope/vasopressor requirement, clinical assessment of

195 ion (33%), mechanical ventilation (26%), and inotrope/vasopressor therapy (26%) were common.

196 ascular dysfunction (47% versus 23% received inotrope/vasopressor therapy; P = 0.02).

197 cal treatment for cardiogenic shock includes inotropes, vasopressors and diuretics.

198 ients with cardiogenic shock unresponsive to inotropes/vasopressors and intraaortic balloon pumps (IA

199 eased significantly, and the requirement for inotropes was reduced significantly.

200 tients who were not status 1A or required >1 inotrope were excluded.

201 Inotropes were not altered, and no transfusions were giv

202 Inotropes were prescribed based on transesophageal echoc

203 Inotropes were used in patients listed for transplant or

204 n, mechanical ventilation, vasopressors, and inotropes when appropriate.

205 operative ejection fraction and the need for inotropes when coming off bypass did not exhibit statist

206 f 200 advanced heart failure patients not on inotropes who met indications for LVAD implantation, com

207 Levosimendan is a new inotrope with calcium sensitization properties that impr

208 Thus, NO(-) is a redox-sensitive positive inotrope with selective venodilator action, whose cardia

209 insufficiency, and 40% were on at least two inotropes with a mean cardiac index of 1.8 L/min/m2.

210 Whether newer inotropes with differing mechanisms of action will reali

211 e pressure >/=24 mm Hg and dependent on >/=2 inotropes with or without intra-aortic balloon pump) wer

212 ntil transplantation; improvement leading to inotrope withdrawal; or death.

213 iogram (80%) and/or the need for intravenous inotropes within 7 days of hospital admission (69%).